AntiArthritis therapies 2005

Expert Opinion on Investigational Drugs

Volumn 14, Issue 4, 2005, Pages 539-543

  Braddock, Martin ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Ankylosing spondylitis; Anti arthritis; CC 10004; HCT 3012; Infliximab; Licofolene; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CC 10004; CELECOXIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; INFLIXIMAB; IRON; LENALIDOMIDE; LICOFELONE; METHOTREXATE; NAPROXEN; NITRONAPROXEN; PHOSPHODIESTERASE IV INHIBITOR; RITUXIMAB; ROFECOXIB; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANEMIA; AREA UNDER THE CURVE; ARTHRITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CROHN DISEASE; DIARRHEA; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG INFUSION; DRUG INFUSION REACTION; DRUG POTENTIATION; DRUG RESEARCH; DRUG SCREENING; DRUG TOLERABILITY; DUODENUM ULCER; GRANULOMA; HUMAN; HYPERTENSION; INFECTION; LIVER TOXICITY; NAIL DISEASE; NONHUMAN; OSTEOARTHRITIS; PERIPHERAL EDEMA; PROCESS OPTIMIZATION; PSORIASIS; PSORIATIC ARTHRITIS; STOMACH ULCER; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; ARTHRITIS; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; NAPROXEN; NITRIC OXIDE DONORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 19044387139     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.4.539     Document Type: Conference Paper

References (20)

1. ANTONI C, KRUEGER GG, DE VLAM K et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT II trial. Ann. Rheum. Dis. (2005) (In press).
2. BRAUN J, BRANDT J, LISTING J et al.: Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondilitis. Ann. Rheum. Dis. (2005) 64:229-234.
3. TALBOT C, SAGAR PM, JOHNSTON MJ, FINAN PJ, BURKE D: Infliximab in the surgical management of complex fistulating and Crohn's disease. Colorectal Dis. (2005) 7:164-168.
4. DOMENECH E, MANOSA M, MASNOU H et al.: Infliximab for the treatment of chronic anemia in Crohn's disease. Am. J. Gastroenterol. (2005) 100:496.
5. HANAUER SB, WAGNER CL, BALA M et al.: Incidence and importance of antibody response to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. (2004) 2:542-553.
6. BAIDOO L, LICHTENSTEIN GR: What next after infliximab? Am. J. Gastroenterol. (2005) 100:80-83.
7. FELICIANI C, ZAMPETTI A, FORLEO P et al.: Nail psoriasis: combined therapy with systemic cyclosporine and topical calcipotriol. J. Cutan. Med. Surg. (2004) 8:122-125.
8. KLARESKOG L, VAN DER HEIJDE D, DE JAGAR JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet (2004) 363:675-681.
9. SAINI R, TUTRONE WD, WEINBERG JM: Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene and pimecrolimus. Curr. Pharm. Design (2005) 11:273-280.
10. SHEN C, ASSCHE GV, COLPAERT S et al.: Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. (2005) 21:251-258.
11. EDWARDS JCW, SZCZEPARISKI L, SZECHINSKI L et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. (2004) 350:2572-2581.
12. SILVERMAN GJ. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum. (2005) 52:371-377.
13. SOWERS JR, WHITE WB, BITT B et al.: The effects of cyclooxygenase-1 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis and Type 2 diabetes mellitus. Arch. Intern. Med. (2005) 165:161-168.
14. MOREAU M, DAMINET S, MARTELPELLETIER J, FERNANDES J, PELLETIER J-P: Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs. J. Vet. Pharmacol. Therap. (2005) 28:81-86.
15. MOLOSTOV G, MORRIS A, ROSE P, BASU S, MULLER G: The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell culture. Br. J. Haematol. (2004) 124:366-375.
16. GALUSTIAN C, LABARTHE M-C, BARTLETT JB, DALGLEISH AG: Thalidomide-derived immunomodulatory drugs as therapeutic targets. Expert Opin. Biol. Ther. (2004) 4:1963-1970.
17. KYLE RA, RAJKUMAR SV: Multiple myeloma. N. Engl. J. Med. (2004) 351:1860-1873.
18. LIST A, KURTIN S, ROE DJ et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. (2005) 352:549-557.
19. TOHNYA TM, NG SS, DAHUT DL et al.: A Phase I study of oral CC-5013 (lenalidomide, revlimid), a thalidomide derivative in patients with refractory metastatic cancer. Clin. Prostate Cancer (2004) 2:241-243.
20. PAYVANDI F, WU L, HALEY M et al.: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNFα. IL-1β and LPS-stimulated human PBMC in a partially IL-10 dependent manner. Cell. Immunol. (2004) 230:81-88.